Endoscopic Ultrasonography Market: as GLOBOCAN 2022's 511,000 annual pancreatic cancer cases and 85 to 90% EUS-FNB diagnostic sensitivity create irreducible tissue acquisition demand that drives the premium EUS-FNB needle market toward 19-gauge and 22-gauge histological core biopsy designs for molecular profiling at USD 200 to USD 400 per needle, so the Cook Medical EchoTip AcuCore May 2024 launch and Limaca Medical Precision GI FDA 510(k) clearance in September 2023 with Breakthrough Device Designation expand competitive alternatives to Medtronic SharkCore and Boston Scientific EchoTip ProCore in the premium FNB segment, and so Boston Scientific's AXIOS stent Japan regulatory approval for gallbladder drainage in 2024 and therapeutic EUS expansion into biliary and pseudocyst drainage are creating new high-value per-procedure device revenue streams at USD 1,800 to USD 2,500 per AXIOS stent that substantially exceed diagnostic EUS-FNA accessory revenue per case.

The global endoscopic ultrasonography market size was USD 1.48 Billion in 2025 and is expected to register a revenue CAGR of 7.2% during the forecast period. Market revenue growth is driven by factors such as pancreatic cancer's position as the sixth leading cause of cancer mortality globally with GLOBOCAN 2022 documenting 511,000 new cases and 467,000 deaths that create irreducible demand for EUS-guided fine needle biopsy as the primary tissue acquisition modality, the structural upgrade of the EUS needle market toward premium 19-gauge and 22-gauge histological core biopsy designs required for molecular biomarker profiling at USD 200 to USD 400 per needle, as well as the therapeutic EUS expansion into biliary drainage and pseudocyst drainage creating new high-value per-procedure device revenue streams. The first driving factor is the pancreatic cancer burden and EUS-FNB diagnostic superiority. GLOBOCAN 2022, published by Bray et al. in CA: A Cancer Journal for Clinicians in 2024, documented 511,000 new pancreatic cancer cases and 467,000 deaths globally in 2022, making pancreatic cancer the sixth leading cause of cancer mortality worldwide at approximately 5% of all cancer deaths. EUS-guided fine needle aspiration and fine needle biopsy provide the primary minimally invasive tissue acquisition modality for pancreatic cancer diagnosis with sensitivity of approximately 85 to 90% documented in published meta-analyses. Olympus Corporation reported Endoscopic Solutions Business revenue of JPY 636,144 Million for FY2025, with the EU-ME3 ultrasound processor and GF-UCT180 and GF-UE290 linear echoendoscopes marketed globally. Boston Scientific reported Endoscopy division net sales of USD 2.687 Billion for FY2024 per SEC 10-K. The second driving factor is Cook Medical's EchoTip AcuCore EUS Biopsy Needle launch in May 2024, designed for precision core biopsies of gastrointestinal lesions using EUS to improve histological core sample acquisition for molecular biomarker profiling. The third driving factor is the Boston Scientific AXIOS stent Japan regulatory approval for gallbladder drainage in 2024, establishing EUS-guided cholecystoduodenostomy as a Japan-reimbursed endoscopic alternative to percutaneous cholecystostomy at USD 1,800 to USD 2,500 per AXIOS stent versus USD 400 to USD 1,200 for conventional biliary metal stents. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the structural upgrade of the EUS needle market toward premium large-calibre 19-gauge and 22-gauge histological core biopsy designs required for comprehensive molecular biomarker profiling of pancreatic and GI malignancies that cannot be adequately completed from 25-gauge cytological aspirate samples. ESMO 2024 clinical practice guidelines recommend comprehensive molecular profiling including KRAS mutation status, SMAD4, TP53, and BRCA1/2 for all advanced pancreatic adenocarcinoma patients, because BRCA-mutated pancreatic cancer responds to PARP inhibitors and olaparib is FDA-approved in that setting, and obtaining sufficient tumour tissue for that molecular panel from an EUS-guided biopsy of a pancreatic head mass requires a 19-gauge core biopsy needle rather than a 25-gauge cytology aspirate. Limaca Medical's Precision GI EUS biopsy needle received FDA 510(k) clearance in September 2023 after FDA Breakthrough Device Designation, featuring a motorised automated rotational cutting mechanism designed to decrease sample tissue fragmentation, inadequate sample quantity, and blood contamination that render EUS-FNA specimens non-diagnostic. The FUJIFILM ARIETTA 750 FF ENDO compatibility with multiple EUS bronchoscope models, announced in September 2024 with Carving Imaging and eFocusing image enhancement, extended FUJIFILM's ultrasound platform into multi-brand compatible EUS processing. The effect on the market is a premium needle market that generates USD 200 to USD 400 per-procedure revenue at 2 to 3 times the per-unit value of standard FNA needles at USD 100 to USD 180. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the pancreatic cancer burden and the clinical guideline position of EUS-FNB as the preferred tissue acquisition modality that cannot be replaced by cross-sectional imaging or percutaneous biopsy in pancreatic head masses where the stomach and duodenum provide the echoendoscope's direct access route for real-time ultrasound-guided needle puncture. GLOBOCAN 2022 documented 511,000 new pancreatic cancer cases and 467,000 deaths globally in 2022, with approximately 80 to 85% of patients presenting with unresectable disease at diagnosis where tissue confirmation for systemic treatment selection is a near-universal diagnostic requirement. The American Society for Gastrointestinal Endoscopy 2022 guideline update recommended EUS-FNB with a dedicated biopsy needle as the preferred approach over EUS-FNA for pancreatic solid masses requiring histological diagnosis, reinforcing the commercial shift toward premium FNB needle procurement. Cook Medical launched the EchoTip AcuCore EUS Biopsy Needle in May 2024, specifically designed to improve core sample acquisition for accurate diagnosis and staging of challenging-to-reach GI lesions, with its core biopsy design retrieving histological tissue columns that support comprehensive molecular biomarker profiling including KRAS, SMAD4, TP53, and BRCA1/2 required by ESMO 2024 guidelines. Limaca Medical's Precision GI EUS biopsy needle with FDA 510(k) clearance in September 2023, featuring motorised automated rotational cutting to reduce sample fragmentation, entered the premium FNB needle segment alongside Medtronic SharkCore and Boston Scientific EchoTip ProCore at USD 200 to USD 400 per needle. The effect on the market is a structural needle market upgrade that multiplies per-procedure EUS accessory revenue above the standard FNA needle baseline. These are some of the key factors driving revenue growth of the market.

The second driver is the therapeutic EUS category generating premium per-procedure device revenue that exceeds diagnostic EUS-FNA accessory consumption by 3 to 5-fold per procedure, driven by lumen-apposing metal stent technology that enables endoscopic internal drainage of biliary structures, pancreatic pseudocysts, and gallbladders without surgical intervention. Boston Scientific's AXIOS stent received Japan regulatory approval for gallbladder drainage in 2024 per the company's FY2024 operational highlights, establishing EUS-guided cholecystoduodenostomy or cholecystogastrostomy using the AXIOS stent as an endoscopic alternative to percutaneous cholecystostomy in high-surgical-risk patients with acute cholecystitis, with the AXIOS stent priced at approximately USD 1,800 to USD 2,500 per unit compared to USD 400 to USD 1,200 for conventional biliary metal stents. EUS-guided pancreatic pseudocyst drainage using lumen-apposing metal stents has replaced surgical cystogastrostomy as the first-line drainage approach at high-volume academic centres. The FUJIFILM ALOKA ARIETTA 850 installation at Fortis Hospital Bengaluru in February 2024 specifically supported non-invasive pancreatic pseudocyst drainage and cancer therapy, demonstrating therapeutic EUS-capable ultrasound system expansion in Asian emerging markets. Boston Scientific Endoscopy reported FY2024 net sales of USD 2.687 Billion growing 8.0% organically, with double-digit growth in endoluminal surgery and single-use imaging platforms as key drivers including AXIOS stent platform sustained strength. The effect on the market is a rapidly growing per-procedure therapeutic EUS device revenue stream that is substantially less price-sensitive than diagnostic EUS procedure costs because therapeutic EUS typically replaces much more expensive surgical or percutaneous interventions, making the per-procedure device cost comparison favourable even at AXIOS stent premium pricing. These are some of the key factors driving revenue growth of the market.

The Cook Medical EchoTip AcuCore EUS Biopsy Needle launch in May 2024 and the Limaca Medical Precision GI FDA 510(k) clearance in September 2023 with Breakthrough Device Designation expand the competitive field for premium EUS-FNB needles beyond the established Medtronic SharkCore and Boston Scientific EchoTip ProCore duopoly, adding motorised rotational cutting capability and improved core tissue architecture retrieval that are clinically differentiated from passive linear needle designs. ESMO 2024 comprehensive molecular profiling requirements for advanced pancreatic adenocarcinoma, including KRAS, SMAD4, TP53, and BRCA1/2 panel testing, structurally sustain premium 19-gauge core biopsy needle demand above standard FNA aspiration needle use.

The third driver is the competitive expansion of EUS ultrasound processor and echoendoscope platform options beyond the Olympus EU-ME3 and GF-UCT180 dominant installed base, driven by FUJIFILM's multi-brand compatible ARIETTA 750 FF ENDO processor and EndoSound's January 2024 FDA-cleared new EUS system platform. In September 2024, FUJIFILM announced ARIETTA 750 FF ENDO compatibility with multiple EUS bronchoscope models, including Carving Imaging and eFocusing image enhancement, positioning the ARIETTA 750 FF ENDO as a multi-brand compatible ultrasound processor that European hospitals with mixed echoendoscope inventories can use with Olympus, Pentax, and FUJIFILM echoendoscopes, reducing procurement risk versus Olympus's EU-ME3 which has limited cross-platform compatibility. In February 2024, FUJIFILM India introduced the ALOKA ARIETTA 850 Diagnostic Ultrasound System with its inaugural installation at Fortis Hospital Bengaluru, supporting pancreatic pseudocyst drainage and cancer therapy and establishing a reference site for FUJIFILM's EUS product portfolio across the Fortis national hospital chain with approximately 150 to 200 Indian EUS-capable hospital programmes concentrated at private tertiary hospitals. In January 2024, EndoSound received FDA 510(k) clearance for its innovative EUS technology, expanding the competitive EUS system market beyond the Olympus-dominant platform. The effect on the market is increased competitive options for hospital EUS programme capital equipment procurement, expanding the addressable market for EUS processor and echoendoscope revenue beyond the Olympus-controlled installed base that has limited competitive platform penetration at established EUS accounts. These are some of the key factors driving revenue growth of the market.

However, the endoscopic ultrasonography market faces adoption constraints from the high capital cost of EUS systems at USD 80,000 to USD 250,000 per complete echoendoscope and processor installation, the EUS operator shortage requiring approximately 150 to 250 supervised procedures to achieve competency that limits EUS programme expansion at hospitals that have invested in EUS systems but lack trained operators, and the improving sensitivity of non-invasive cross-sectional imaging including contrast-enhanced pancreatic protocol CT and MRCP for pancreatic and biliary pathology that reduces the incremental EUS referral volume in markets with strong radiology imaging capability. These factors substantially limit endoscopic ultrasonography market growth over the forecast period.

Based on product, the global EUS market is segmented into echoendoscopes, ultrasound processors, EUS-FNA and EUS-FNB biopsy needles, probes, and accessories. Echoendoscopes hold the largest revenue share at approximately 34% of 2025 market revenue, with linear array echoendoscopes priced at USD 35,000 to USD 60,000 per instrument and Olympus's GF-UCT180 and GF-UE290 paired with the EU-ME3 processor representing the leading EUS platform globally. FUJIFILM's EG-UC5T and Pentax Medical's EG-3870UTK slim linear echoendoscope provide competitive alternatives. EUS-FNA and EUS-FNB biopsy needles are expected to register the fastest revenue growth rate over the forecast period, driven by the shift from 25-gauge cytology aspiration to premium 19-gauge and 22-gauge histological core biopsy needles for molecular biomarker profiling at USD 200 to USD 400 per needle.

Based on application, the global EUS market is segmented into oncology, gastroenterology, and interventional EUS. Oncology holds the largest application revenue share, encompassing EUS-guided tissue acquisition for pancreatic cancer diagnosis, oesophageal cancer T and N staging, gastric cancer locoregional staging, and submucosal GI tumour characterisation. Therapeutic EUS is expected to register the fastest revenue growth rate over the forecast period, driven by AXIOS stent-based biliary drainage, pancreatic pseudocyst drainage, and gallbladder drainage at USD 1,800 to USD 2,500 per AXIOS stent that command 3 to 5 times the per-procedure device revenue of diagnostic EUS-FNA needle consumption.

Based on end-use, the global EUS market is segmented into hospitals and cancer centres, and ambulatory surgical centres. Hospitals and cancer centres hold the dominant revenue share because EUS echoendoscope capital equipment and therapeutic EUS drainage procedures with AXIOS stents are concentrated at academic medical centres and tertiary cancer hospitals with trained EUS endoscopists and dedicated pancreatic disease programmes. CMS reimbursement under CPT code 43242 for EUS with trans-luminal needle aspiration provides the US reimbursement framework supporting EUS programme economics. Olympus's EU-ME3 and GF-UCT180 installed base at US, European, and Japanese academic medical centres anchors the hospital-concentrated revenue distribution.

Based on regional analysis, the endoscopic ultrasonography market in North America accounted for the largest revenue share in 2025 at approximately 40% of global revenue. The United States leads through the highest per-procedure EUS device pricing globally, the broadest commercial adoption of premium EUS-FNB needle platforms including Medtronic SharkCore, Boston Scientific EchoTip ProCore, and Cook EchoTip AcuCore at academic medical centres, and the most active commercial development of therapeutic EUS applications. CMS reimbursement under CPT codes 43242 and 43253 provides the US reimbursement framework supporting EUS programme economics. Limaca Medical's Precision GI EUS biopsy needle, cleared by FDA in September 2023 after Breakthrough Device Designation, targets the US academic medical centre market as a premium alternative.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, the United Kingdom, the Netherlands, and Italy represent the five largest national EUS device markets. ESGE EUS Clinical Guidelines maintain EUS as the recommended staging procedure for oesophageal cancer T and N staging and pancreatic cancer locoregional staging, with oesophageal EUS staging representing a larger proportion of European EUS volume relative to North America where pancreatic mass evaluation dominates. FUJIFILM ARIETTA 750 FF ENDO multi-brand compatible processor targets European institutions with mixed echoendoscope inventories. Iran-US sanctions and associated disruption to specialty fluoropolymer supply chains serving European echoendoscope production have maintained elevated component costs through 2026.

The market in Asia Pacific is expected to register the fastest revenue growth rate over the forecast period. Japan, China, South Korea, India, and Australia represent the five largest national EUS markets. Japan maintains one of the world's most advanced EUS clinical programmes with Olympus domestic installed base leadership and NHI coverage for EUS procedures. FUJIFILM India's February 2024 ALOKA ARIETTA 850 installation at Fortis Hospital Bengaluru illustrates the growing Indian tertiary hospital EUS market. China's rapidly expanding tertiary hospital gastroenterology infrastructure is generating new EUS system procurement, leaving more room for Asia Pacific market growth than in North America where EUS penetration at academic centres is already higher.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil, Mexico, Colombia, and Argentina represent the four largest national EUS markets. Brazil's major academic centres in Sao Paulo have established EUS programmes. Olympus Latin America's January 2025 Sur Medical Chile distribution acquisition expands direct echoendoscope distribution into the Chilean market. Global supply chain disruptions affecting polymer echoendoscope component imports continue to affect EUS equipment import costs in Latin American markets through 2026.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia, the UAE, Turkey, Egypt, and South Africa represent the primary national EUS markets. Saudi Arabia's King Faisal Specialist Hospital and Research Centre and the UAE's Cleveland Clinic Abu Dhabi operate EUS programmes at their advanced gastroenterology units, with Olympus echoendoscopes distributed through established Saudi and UAE medical device distribution partnerships. South Africa's Netcare and Life Healthcare private hospital groups perform EUS at selected oncology centres with Olympus and FUJIFILM echoendoscopes.